CJC-1295
CJC-1295 is a synthetic GHRH analogue based on the first 29 amino acids of native GHRH, modified at positions 2, 8, 15, and 27 to resist DPP-IV cleavage. The DAC (Drug Affinity Complex) variant adds a maleimidopropionyl chain that binds endogenous albumin, extending half-life from minutes to roughly 6–8 days.1
CJC-1295 at a glance
CJC-1295 is a synthetic GHRH analogue based on the first 29 amino acids of native GHRH, modified at positions 2, 8, 15, and 27 to resist DPP-IV cleavage. The DAC (Drug Affinity Complex) variant adds a maleimidopropionyl chain that binds endogenous albumin, extending half-life from minutes to roughly 6–8 days.1
At Luxbae we prescribe both formulations: the no-DAC version (Mod-GRF 1-29) for clients who want pulsatile physiology with daily dosing, and CJC-1295 with DAC for those preferring twice-weekly cadence. Both are typically stacked with a ghrelin agonist like Ipamorelin to engage both arms of GH release.
Binds pituitary GHRH receptors, stimulating somatotroph GH release in a manner that respects native somatostatin feedback.2
DAC extends half-life via albumin binding; no-DAC restores natural pulsatility. We match formulation to your goals and dosing tolerance.
What the research actually shows
CJC-1295 has been studied across multiple modalities. The summaries below cite peer-reviewed sources; individual response varies and is not guaranteed.
Sustained increases in 24-hour GH and IGF-1 reported in clinical pharmacology studies of CJC-1295.1
Lean mass and adiposity shifts consistent with restored GH axis in middle-aged adults.3
GHRH analogues increase slow-wave sleep in older adults.4
Improved subjective recovery is consistently reported on Ipamorelin/CJC stacks.
IGF-1 mediated improvements in collagen synthesis and dermal hydration.
Both DAC and no-DAC versions allow protocol tailoring.
Your consultation is complimentary. Our medical team reviews your goals, current treatments, and history before recommending anything.
How a CJC-1295 protocol typically runs at Luxbae
Dosing, cadence, and delivery method are tailored to you. The outline below describes the most common variant; your provider personalizes based on labs, current treatments, and goals.
Baseline IGF-1, fasting glucose, A1C, and full history reviewed.
Daily no-DAC pre-sleep, or 2×/week DAC; titrated by IGF-1 response.
IGF-1 rechecked at 6–8 weeks; dosing adjusted to age-appropriate range.
Typically combined with Ipamorelin for ghrelin-receptor synergy.
Frequently sequenced alongside
- Ipamorelin for ghrelin-receptor synergy.
- CJC-1295 / Ipamorelin Blend — the signature stack.
- Tesamorelin if visceral fat is the priority.
- IGF-1 LR3 for direct IGF-1 support.
- Morpheus8 for collagen amplification.
Who it’s for — and who should avoid it
CJC-1295 eligibility is confirmed during your medical consultation; your full medical history must be disclosed.
- Adults with declining GH axis.
- Body-composition or recovery goals.
- Aesthetic clientele pursuing skin and connective-tissue support.
- No history of malignancy.
- Pregnancy or breastfeeding.
- Children and adolescents.
- Acute infection or autoimmune flare.
- Known peptide hypersensitivity.
- Active or recent malignancy.
- Untreated severe sleep apnea.
- Active proliferative retinopathy.
Possible side effects
Injection-site reactions, transient water retention, occasional headache, mild fatigue at initiation.
FDA & regulatory note
CJC-1295 is not FDA-approved. Tesamorelin (a related GHRH analogue) is FDA-approved as Egrifta for HIV-associated lipodystrophy.
Dr. Ernst von Schwarz, MD, PhD
Professor Dr. Ernst von Schwarz — triple board-certified clinical and academic cardiologist, clinical professor of medicine at UCLA, and a three-decade pioneer in stem cell and regenerative medicine research — personally directs Luxbae’s peptide program. He has authored more than 150 peer-reviewed scientific papers and lectures internationally on cardiovascular and regenerative medicine. Every CJC-1295 protocol at Luxbae is prescribed and monitored under his direction.
Meet Dr. von SchwarzCJC-1295 FAQ
DAC or no-DAC?
Will my IGF-1 go up?
Is this HGH?
Can women use it?
How long until I notice changes?
Stacking with Ipamorelin?
Clinical References
Reviewed by Dr. Ernst von Schwarz and the Luxbae medical team. Statements on this page are educational and supported by the following peer-reviewed sources. Individual results vary.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. View
- Sackmann-Sala L, et al. GHRH analog therapy: clinical applications. Endocr Rev. 2008. View
- Khorram O, et al. Effects of [Nle27]GHRH(1-29)-NH2 administration on the GH-IGF axis. J Clin Endocrinol Metab. 1997;82(5):1472-1479. View
- Vitiello MV, et al. GHRH stimulates slow wave sleep in older adults. J Gerontol A. 1997. View
Start your CJC-1295 protocol at Luxbae West Hollywood
Your consultation is complimentary. We’ll walk you through how CJC-1295 fits your goals, what labs (if any) we’d run, and how it would sequence with the rest of your aesthetic plan.